In horses and humans, tendon injuries are a significant problem. Not only can they occur in both athletes and nonathletes, they require lengthy periods of recuperation and undergo poor natural regeneration, which leads to high reinjury rates. Embryonic stem cells (ESCs) may provide a renewable source of allogeneic cells to use in clinical applications to aid tissue regeneration. Equine ESCs can undergo tenocyte differentiation in vivo and in vitro, but the immune properties of tenocytes isolated from either ESCs or tissues have not previously been characterized. Here, we demonstrate that equine tenocytes derived from fetal and adult tendon tissue and ESCs express robust levels of major histocompatibility complex (MHC) I but no MHC II in response to inflammatory cytokine interferon gamma (IFNγ). However, MHC expression does not affect their allorecognition by peripheral blood mononuclear cells in vitro. Adult and fetal tenocytes remain immune privileged and strongly immune suppressive in both the presence and absence of exogenously applied IFNγ. In contrast, ESC-derived tenocytes are immune privileged even in the presence of IFNγ, but they are only weakly immune suppressive in the presence but not in the absence of exogenously applied IFNγ. This is despite ESC-tenocytes expressing a number of genes involved in immune modulation at significantly higher levels than those expressed by adult and fetal tenocytes when in standard, nonstimulated monolayer culture. Together, this work suggests that, similar to other fibroblasts, tenocytes have immune modulatory properties, and that culture-expanded tenocytes derived from primary tissues or ESCs may be safe to use in clinical transplantations to injured tendons of unrelated animals.
Get full access to this article
View all access options for this article.
References
1.
WilliamsRB, HarkinsLS and WoodJLN. (2001). Racehorse injuries, clinical problems and fatalities recorded on British racecourses from flat racing and National Hunt racing during 1996, 1997 and 1998. Equine Vet J, 33:478–486.
2.
KannusP. (1997). Tendons—a source of major concern in competitive and recreational athletes. Scand J Med Sci Sports, 7:53–54.
3.
SpaasJH, GuestDJ and Van de WalleGR. (2012). Tendon regeneration in human and equine athletes: Ubi Sumus-Quo Vadimus (where are we and where are we going to)?. Sports Med, 42:871–890.
4.
Patterson-KaneJC and RichT. (2014). Achilles tendon injuries in elite athletes: lessons in pathophysiology from their equine counterparts. ILAR J, 55:86–99.
5.
Dyson SJ. (2004). Medical management of superficial digital flexor tendonitis: a comparative study in 219 horses (1992–2000). Equine Vet J, 36:415–419.
6.
LamKH, ParkinTDH, RiggsCM and MorganKL. (2007). Descriptive analysis of retirement of Thoroughbred racehorses due to tendon injuries at the Hong Kong Jockey Club (1992–2004). Equine Vet J, 39:143–148.
7.
BeredjiklianPK, FavataM, CartmellJS, FlanaganCL, CrombleholmeTM and SoslowskyLJ. (2003). Regenerative versus reparative healing in tendon: a study of biomechanical and histological properties in fetal sheep. J Biomed Eng, 31:1143–1152.
8.
FavataM, BeredjiklianPK, ZgonisMH, BeasonDP, CrombleholmeTM, JawadAF and SoslowskyLJ. (2006). Regenerative properties of fetal sheep tendon are not adversely affected by transplantation into an adult environment. J Orthop Res, 24:2124–2132.
9.
TangQM, ChenJL, ShenWL, YinZ, LiuHH, FangZ, HengBC, OuyangHW and ChenX. (2014). Fetal and adult fibroblasts display intrinsic differences in tendon tissue engineering and regeneration. Sci Rep, 4:5515.
10.
BachBR Jr., TradonskyS, BojchukJ, LevyME, Bush-JosephCA and KhanNH. (1998). Arthroscopically assisted anterior cruciate ligament reconstruction using patellar tendon autograft. Five- to nine-year follow-up evaluation. Am J Sports Med, 26:20–29.
11.
LongoUG, LambertiA, MaffulliN and DenaroV. (2010). Tendon augmentation grafts: a systematic review. Br Med Bull, 94:165–188.
12.
MinamiA, UsuiM, IshiiS and KobayashiH. (1983). The in vivo effects of various immunoreactive treatments on allogeneic tendon grafts. J Hand Surg Am, 8:888–893.
13.
LiX, ZhouSG, ImrehMP, Ahrlund-RichterL and AllenWR. (2006). Horse embryonic stem cell-like cell lines from the proliferation of inner cell mass cells. Stem Cells Dev, 15:523–531.
14.
GuestDJ and AllenWR. (2007). Expression of cell surface antigens and embryonic stem cell pluripotency genes in equine blastocysts. Stem Cells Dev, 16:789–795.
15.
GuestDJ, SmithMRW and AllenWR. (2010). Equine embryonic stem-like cells and mesenchymal stromal cells have different survival rates and migration patterns following their injection into damaged superficial digital flexor tendons. Equine Vet J, 42:636–642.
16.
BarsbyT and GuestD. (2013). Transforming growth factor beta3 promotes tendon differentiation of equine embryo-derived stem cells. Tissue Eng Part A, 19:2156–2165.
17.
BecerraP, Valdes VaquezM, DudhiaJ, Fiske-JacksonAR, NevesF, HartmanNG and SmithRKW. (2013). Distribution of injected technetium99m labeled mesenchymal stem cells in horses with naturally occuring tendinopathy. J Orthop Res, 31:1096–1102.
18.
BarsbyT, BavinEP and GuestDJ. (2014). Three-dimensional culture and transforming growth factor beta3 synergistically promote tenogenic differentiation of equine embryo-derived stem cells. Tissue Eng Part A, 20:2604–2613.
19.
BavinEP, AtkinsonF, BarsbyT and GuestDJ. (2017). Scleraxis is essential for tendon differentiation by equine embryonic stem cells and in equine fetal tenocytes. Stem Cells Dev, 26:441–450.
20.
PatersonY, RashN, GarvicanE, PaillotR and GuestDJ. (2014). Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro. Stem Cell Res Ther, 5:90.
21.
CarradeDD, LameMW, KentMS, ClarkKC, WalkerNJ and BorjessonDL. (2012). Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med, 4:1–11.
22.
Carrade HoltDD, WoodJA, GranickJL, WalkerNJ, ClarkKC and BorjessonDL. (2014). Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev, 23:1258–1265.
23.
BarrachinaL, RemachaAR, RomeroA, VazquezFJ, AlbaredaJ, PradesM, GosalvezJ, RoyR, ZaragozaP, Martin-BurrielI and RodellarC. (2017). Priming equine bone marrow-derived mesenchymal stem cells with proinflammatory cytokines: implications in immunomodulation-immunogenicity balance, cell viability, and differentiation potential. Stem Cells Dev, 26:15–24.
24.
AggarwalS and PittengerMF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
25.
GaoF, ChiuSM, MotanDA, ZhangZ, ChenL, JiHL, TseHF, FuQL and LianQ. (2016). Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis, 7:e2062.
26.
DakinSG, WerlingD, HibbertA, AbayasekaraDR, YoungNJ, SmithRK and DudhiaJ. (2012). Macrophage sub-populations and the lipoxin A4 receptor implicate active inflammation during equine tendon repair. PLoS One, 7:e32333.
27.
DakinSG, DudhiaJ, WerlingNJ, WerlingD, AbayasekaraDR and SmithRK. (2012). Inflamm-aging and arachadonic acid metabolite differences with stage of tendon disease. PLoS One, 7:e48978.
28.
MillarNL, MurrellGA and McInnesIB. (2017). Inflammatory mechanisms in tendinopathy—towards translation. Nat Rev Rheumatol, 13:110–122.
29.
ReesJD, StrideM and ScottA. (2014). Tendons—time to revisit inflammation. Br J Sports Med, 48:1553–1557.
30.
DakinSG, DudhiaJ and SmithRK. (2013). Science in brief: resolving tendon inflammation. A new perspective. Equine Vet J, 45:398–400.
31.
CleggPD, StrassburgS and SmithRK. (2007). Cell phenotypic variation in normal and damaged tendons. Int J Exp Path, 88:227–235.
32.
HosakaY, KirisawaR, YamamotoE, UedaH, IwaiH and TakehanaK. (2002). Localisation of cytokines in tendinocytes of the superficial digital flexor tendon in the horse. J Vet Med Sci, 64:945–947.
33.
McClellanA, EvansR, SzeC, KanS, PatersonY and GuestD. (2019). A novel mechanism for the protection of embryonic stem cell derived tenocytes from inflammatory cytokine interleukin 1 beta. Sci Rep, 9:2755.
34.
CarradeDD and BorjessonDL. (2013). Immunomodulation by mesenchymal stem cells in veterinary species. Comp Med, 63:207–217.
35.
Caplan AI. (2017). Mesenchymal stem cells: time to change the name! Stem Cells Transl Med, 6:1445–1451.
36.
CaplanAI and DennisJE. (2006). Mesenchymal stem cells as trophic mediators. J Cell Biochem, 98:1076–1084.
37.
DenuRA, NemcekS, BloomDD, GoodrichAD, KimJ, MosherDF and HemattiP. (2016). Fibroblasts and mesenchymal stromal/stem cells are phenotypically indistinguishable. Acta Haematol, 136:85–97.
38.
BouffiC, BonyC, JorgensenC and NoëlD. (2011). Skin fibroblasts are potent suppressors of inflammation in experimental arthritis. Ann Rheum Dis, 70:1671–1676.
39.
Korn JH. (1981). Modulation of lymphocyte mitogen responses by cocultured fibroblasts. Cell Immunol, 63:374–384.
40.
ShimabukuroY, MurakamiS and OkadaH. (1992). Interferon-gamma-dependent immunosuppressive effects of human gingival fibroblasts. Immunology, 76:344–347.
41.
DonnellyJJ, XiMS and RockeyJH. (1993). A soluble product of human corneal fibroblasts inhibits lymphocyte activation. Enhancement by interferon-gamma. Exp Eye Res, 56:157–165.
42.
LeJM and VilcekJ. (1987). Accessory function of human fibroblasts in mitogen-stimulated interferon-gamma production by T lymphocytes. Inhibition by interleukin 1 and tumor necrosis factor. J Immunol, 139:3330–3337.
43.
HaniffaMA, CollinMP, BuckleyCD and DazziF. (2009). Mesenchymal stem cells: the fibroblasts' new clothes?. Haematologica, 94:258–263.
44.
PaillotR, ProwseL, MontessoF, HuangCM, BarnesH and EscalaJ. (2013). Whole inactivated equine influenza vaccine: efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity. Vet Microbiol, 162:396–407.
45.
PatroR, DuggalG, LoveMI, IrizarryRA and KingsfordC. (2017). Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods, 14:417–419.
46.
SonesonC, LoveMI and RobinsonMD. (2015). Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res, 4:1521.
47.
LoveMI, HuberW and AndersS. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 15:550.
48.
MohibK, AlkhameesB, ZeinHS, AllanD and WangL. (2012). Embryonic stem cell-derived factors inhibit T effector activation and inudce T regulatory cells by suppressing PKC-θ activation. PLoS One, 7:e3420.
49.
MohibK, AllanD and WangL. (2010). Human embryonic stem cell-extracts inhibit the differentiation and function of monocyte-derived dendritic cells. Stem Cell Rev Rep, 6:611–621.
50.
KochCA, GeraldesP and PlattJL. (2008). Immunosuppression by embryonic stem cells. Stem Cells, 26:89–98.
51.
DrukkerM, KatchmanH, KatzG, Even-Tov FriedmanS, ShezenE, HornsteinE, MandelboimO, ReisnerY and BenvenistyN. (2006). Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells, 24:221–229.
52.
FandrichF, DresskeB, BaderM and SchulzeM. (2002). Embryonic stem cells share immune-privileged features relevant for tolerance induction. J Mol Med, 80:343–350.
FairchildPJ, RobertsonNJ, MingerSL and WaldmannH. (2007). Embryonic stem cells: protecting pluripotency from alloreactivity. Curr Opin Immunol, 19:596–602.
55.
RobertsonNJ, BrookFA, GardnerRL, CobboldSP, WaldmannH and FairchildPJ. (2007). Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci U S A, 104:20920–20925.
56.
YuanX, ZhangH, WeiY and HuS. (2007). Embryonic stem cell transplantation for the treatment of myocardial infarction: immune privilege or rejection. Transpl Immunol, 18:88–93.
57.
BifariF, PacelliL and KramperaM. (2010). Immunological properties of embryonic and adult stem cells. World J Stem Cells, 2:50–60.
58.
DrukkerM. (2008). Immunological Considerations for Cell Therapy Using Human Embryonic Stem Cell Derivatives. Stem Book, Cambridge.
59.
YenBL, ChangCJ, LiuK-J, ChenYC, HuH-I, BaiC-H and YenM-L. (2009). Brief report—human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells, 27:451–456.
60.
LuiPP, KongSK, LauPM, WongYM, LeeYW, TanC and WongOT. (2014). Immunogenicity and escape mechanisms of allogeneic tendon-derived stem cells. Tissue Eng Part A, 20:3010–3020.
61.
ShenW, ChenJ, YinZ, ChenX, LiuH, HengBC, ChenW and OuyangHW. (2012). Allogenous tendon stem/progenitor cells in silk scaffold for functional shoulder repair. Cell Transplant, 21:943–958.
62.
LuiPP, KongSK, LauPM, WongYM, LeeYW, TanC and WongOT. (2014). Allogeneic tendon-derived stem cells promote tendon healing and suppress immunoreactions in hosts: in vivo model. Tissue Eng Part A, 20:2998–3009.
63.
BeertsC, SulsM, BroeckxSY, SeysB, VandenbergheA, DeclercqJ, DuchateauL, VidalMA and SpaasJH. (2017). Tenogenically induced allogeneic peripheral blood mesenchymal stem cells in allogeneic platelet-rich plasma: 2-year follow-up after tendon or ligament treatment in horses. Front Vet Sci, 4:158.
64.
CassanoJM, FortierLA, HicksRB, HarmanRM and Van de WalleGR. (2018). Equine mesenchymal stromal cells from different tissue sources display comparable immune-related gene expression profiles in response to interferon gamma (IFN)-gamma. Vet Immunol Immunopathol, 202:25–30.
65.
SchnabelLV, PezzaniteLM, AntczakDF, FelippeMJ and FortierLA. (2014). Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro. Stem Cell Res Ther, 5:13.
66.
PrasannaSJ, GopalakrishnanD, ShankarSR and VasandanAB. (2010). Pro-inflammatory cytokines, IFNγ and TNFα, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One, 5:e9016.
67.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniFC, KrauseDS, DeansRJ, KeatingA, ProckopDJ and HorwitzEM. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
68.
ShiY, SuJ, RobertsAI, ShouP, RabsonAB and RenG. (2012). How mesenchymal stem cells interact with tissue immune responses. Trends Immunol, 33:136–143.
69.
VolarevicV, GazdicM, Simovic MarkovicB, JovicicN, DjonovV and ArsenijevicN. (2017). Mesenchymal stem cell-derived factors: immuno-modulatory effects and therapeutic potential. Biofactors, 43:633–644.
70.
LeeRH, YuJM, FoskettAM, PeltierG, ReneauJC, BazhanovN, OhJY and ProckopDJ. (2014). TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc Natl Acad Sci U S A, 111:16766–16771.
71.
LeeMW, RyuS, KimDS, SungKW, KooHH and YooKH. (2015). Strategies to improve the immunosuppressive properties of human mesenchymal stem cells. Stem Cell Res Ther, 6:179.
72.
SioudM, MobergslienA, BoudabousA and FloisandY. (2011). Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol, 38:385–390.
73.
SioudM, MobergslienA, BoudabousA and FloisandY. (2010). Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol, 71:267–274.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
